Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomised, Placebo-Controlled Studies.

CONCLUSIONS: No new safety signals were identified compared to previously reported data. Risk did not increase with longer or higher CZP exposure.
PMID: 32531798 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - June 11, 2020 Category: Dermatology Authors: Blauvelt A, Paul C, van de Kerkhof P, Warren RB, Gottlieb AB, Langley RG, Brock F, Arendt C, Boehnlein M, Lebwohl M, Reich K Tags: Br J Dermatol Source Type: research